The effects of itraconazole on inflammatory bowel disease activity in patients treated for histoplasmosis

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue 9, 2010, Pages 1207-1209

  Samuel, S ^a   Loftus Jr , E V ^a   Sandborn, W J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INFLIXIMAB; ITRACONAZOLE; TUMOR NECROSIS FACTOR ALPHA;

BACTERIAL INFECTION; CELL ADHESION; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG EFFECT; ENDOSCOPY; ENTERITIS; HISTOPLASMOSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LETTER; NONHUMAN; PRIORITY JOURNAL; REMISSION; SURGICAL APPROACH; ULCERATIVE COLITIS;

ANTIFUNGAL AGENTS; HISTOPLASMOSIS; HUMANS; INFLAMMATORY BOWEL DISEASES; ITRACONAZOLE;

EID: 78649467925     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04444.x     Document Type: Letter

References (4)

1. Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther 2009; 30: 253-64.
2. Thapa D, Lee JS, Park SY, et al. Clotrimazole ameliorates intestinal inflammation and abnormal angiogenesis by inhibiting interleukin-8 expression through a nuclear factor-kappaB-dependent manner. J Pharmacol Exp Ther 2008; 327: 353-64.
3. Thapa D, Lee JS, Park MA, et al. Inhibitory effects of clotrimazole on TNF-alphainduced adhesion molecule expression and angiogenesis. Arch Pharm Res 2009; 32: 593-603.
4. Takahashi H, Abe M, Sugawara T, et al. Clotrimazole, an imidazole antimycotic, is a potent inhibitor of angiogenesis. Jpn J Cancer Res 1998; 89: 445-51.